Avidity Biosciences Inc (NASDAQ: RNA) kicked off on Monday, up 4.35% from the previous trading day, before settling in for the closing price of $43.25. Over the past 52 weeks, RNA has traded in a range of $5.97-$56.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 148.90%. While this was happening, its average annual earnings per share was recorded 3.40%. With a float of $108.28 million, this company’s outstanding shares have now reached $119.31 million.
The extent of productivity of a business whose workforce counts for 253 workers is very important to gauge. In terms of profitability, gross margin is 80.79%, operating margin of -3209.35%, and the pretax margin is -2772.45%.
Avidity Biosciences Inc (RNA) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Avidity Biosciences Inc is 9.24%, while institutional ownership is 101.08%. The most recent insider transaction that took place on Nov 18 ’24, was worth 1,028,520. In this transaction Chief Human Resources Officer of this company sold 25,000 shares at a rate of $41.14, taking the stock ownership to the 94,018 shares. Before that another transaction happened on Nov 19 ’24, when Company’s Director sold 3,323 for $42.12, making the entire transaction worth $139,973. This insider now owns 14,830 shares in total.
Avidity Biosciences Inc (RNA) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 3.40% per share during the next fiscal year.
Avidity Biosciences Inc (NASDAQ: RNA) Trading Performance Indicators
Take a look at Avidity Biosciences Inc’s (RNA) current performance indicators. Last quarter, stock had a quick ratio of 17.76. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 540.68.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.90, a number that is poised to hit -0.76 in the next quarter and is forecasted to reach -3.12 in one year’s time.
Technical Analysis of Avidity Biosciences Inc (RNA)
The latest stats from [Avidity Biosciences Inc, RNA] show that its last 5-days average volume of 0.95 million was inferior to 1.31 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 25.13%. Additionally, its Average True Range was 3.06.
During the past 100 days, Avidity Biosciences Inc’s (RNA) raw stochastic average was set at 42.67%, which indicates a significant increase from 34.12% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 97.26% in the past 14 days, which was higher than the 65.85% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $45.51, while its 200-day Moving Average is $35.31. Now, the first resistance to watch is $46.26. This is followed by the second major resistance level at $47.40. The third major resistance level sits at $48.81. If the price goes on to break the first support level at $43.71, it is likely to go to the next support level at $42.30. Assuming the price breaks the second support level, the third support level stands at $41.16.
Avidity Biosciences Inc (NASDAQ: RNA) Key Stats
The company with the Market Capitalisation of 5.47 billion has total of 119,309K Shares Outstanding. Its annual sales at the moment are 9,560 K in contrast with the sum of -212,220 K annual income. Company’s last quarter sales were recorded 2,340 K and last quarter income was -80,400 K.
